Search Results

You are looking at 31 - 40 of 122 items for :

  • Cushing���s disease x
  • Refine by Access: All content x
Clear All
Open access

Grethe Å Ueland, Thea Grinde, Paal Methlie, Oskar Kelp, Kristian Løvås, and Eystein S Husebye

adrenal tumors and subclinical Cushing’s syndrome: a systematic review and meta-analysis . European Journal of Endocrinology 2016 175 R283 – R295 . ( ) 4 Debono M Bradburn M Bull M Harrison B Ross RJ

Open access

Liza Das, Kim Vaiphei, Ashutosh Rai, Chirag Kamal Ahuja, Paramjeet Singh, Ishani Mohapatra, Rajesh Chhabra, Anil Bhansali, Bishan Dass Radotra, Ashley B Grossman, Márta Korbonits, and Pinaki Dutta

review of literature . Medicine 2019 98 e17772. ( ) 7 Gezer E Selek A Cetinarslan B Canturk Z Tarkun I Ceylan S The coexistence of infundibular pituicytoma and Cushing’s disease due to

Open access

Jülide Durmuşoğlu, Henri J L M Timmers, Pepijn van Houten, Johan F Langenhuijsen, Ad R M M Hermus, and Annenienke C van de Ven

hormone-specific symptoms and signs in patients ( 9 ). The most common clinical presentation of functional ACC is Cushing’s syndrome ( 9 , 10 , 11 ). Venous thromboembolism (VTE) is a potential fatal complication ( 12 ). One might expect a high

Open access

Karim Gariani and François R Jornayvaz

causes of NAFLD. Hormone Gland of origin Example of disease Cortisol - Pituitary gland (ACTH) - Adrenal gland (cortisol) - Cushing’s disease - Cushing’s syndrome - Exogenous corticoid administration Thyroxine (T4

Open access

V Guarnotta, C Di Stefano, A Santoro, A Ciresi, A Coppola, and C Giordano

disease . European Journal of Endocrinology 2007 157 . ( ) 29 Arnaldi G Scandali VM Trementino L Cardinaletti M Appolloni G Boscaro M . Pathophysiology of dyslipidemia in Cushing’s syndrome

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ, and Albert Beckers

preferentially to SST5 and SST2 ( 20 ). In the clinical setting, pasireotide is used in either short-acting or long-acting depot formulations for the treatment of Cushing’s disease and acromegaly ( 21 , 22 ). In acromegaly, pasireotide LAR is indicated for

Open access

Majunath R Goroshi, Swati S Jadhav, Anurag R Lila, Rajeev Kasaliwal, Shruti Khare, Chaitanya G Yerawar, Priya Hira, Uday Phadke, Hina Shah, Vikram R Lele, Gaurav Malhotra, Tushar Bandgar, and Nalini S Shah

Introduction Ectopic adrenocorticotrophic hormone (ACTH) syndrome (EAS) is a rare disorder, accounting for 5–15% cases of endogenous Cushing’s syndrome (CS) ( 1 , 2 ). Although initially construed to be caused by malignant tumours (such as

Open access

Dorte Glintborg, Katrine Hass Rubin, Mads Nybo, Bo Abrahamsen, and Marianne Andersen

with the ICD10 diagnoses pituitary disease (D352 (benign pituitary tumor), E236 (other pituitary disease), and D353 (craniopharyngeoma)), E220 (acromegaly), E221 (hyperprolactinemia), E24 (Cushing’s syndrome), E25 (adrenogenital syndrome), and Q96

Open access

Marcus Quinkler, Bertil Ekman, Claudio Marelli, Sharif Uddin, Pierre Zelissen, Robert D Murray, and on behalf of the EU-AIR Investigators

Addison’s disease and in subjects adrenalectomized for Cushing’s disease: comparison of various glucocorticoids . Journal of Clinical Endocrinology and Metabolism 1982 55 551 – 559 . ( doi:10.1210/jcem-55-3-551 ) 11 Orth DN Kovacs WJ

Open access

Anne Jouinot, Bernard Royer, Etienne Chatelut, Sotheara Moeung, Guillaume Assié, Audrey Thomas-Schoemann, Jérôme Bertherat, François Goldwasser, and Benoit Blanchet

Bou Khalil R Silvera S Guignat L Guibourdenche J Abbas H Legmann P Bertagna X Bertherat J. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center . European Journal of Endocrinology 2012 167 473 – 481